The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD).
Abstract
A new combination chemotherapy program (M-BACOD) was administered to 101 patients with advanced diffuse histiocytic and diffuse undifferentiated lymphoma (DHL and DUL). High dose methotrexate (M) 3 g/m2 with leucovorin factor rescue was given on day 14 between cycles of bleomycin (B), adriamycin (A), cyclophosphamide (C), oncovin (O), and dexamethasone (D) administered every 3 weeks for 10 cycles. The complete remission rate (CR) was 72% in all 101 patients or 77% in 95 evaluable patients. The median follow-up is 3 yr 2 mo with one-third of CR patients followed beyond 4 yr. Twenty-six percent of CR patients have relapsed with a projected 5-yr survival rate of 80% (5-yr disease-free rate 65%). The overall survival of all 101 study patients reaches a plateau at 59% projected out to 5 yr. Patients with prior therapy had a significantly lower CR rate than those without prior treatment (p = 0.001); however, no other unfavorable prognostic characteristics could be identified. Relapse in the central nervous system CNS occurred in only 5.4% of CR patients. M-BACOD results in prolonged survival and possible cure in a high proportion of all patients with DHL and DUL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Report of the Committee on Hodgkin's Disease Staging Classification.
Carbone, P. P., Kaplan, H. S., Musshoff, K., Smithers, D. W., & Tubiana, M. (1971) · PubMed · Cited by 4,166
A generalized Wilcoxon test for comparing arbitrarily singly-censored samples
Gehan, E. A. (1965) · Biometrika · doi:10.1093/biomet/52.1-2.203 · Cited by 3,406
New Approaches to Cancer Chemotherapy with Methotrexate
Bleich, H. L., Boro, E. S., Frei, E., Jaffe, N., Tattersall, M. H. N., Pitman, S., & Parker, L. (1975) · New England Journal of Medicine · doi:10.1056/nejm197504172921607 · Cited by 230
Self-citationCentral nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis
Litam, J., Cabanillas, F., Smith, T., et al. (1979) · Blood · doi:10.1182/blood.v54.6.1249.1249 · Cited by 115
Cited by
Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M., Glick, J. H., Coltman, C. A., & Miller, T. P. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304083281404 · Cited by 2,149
The Pharmacology and Clinical Use of Methotrexate
Jolivet, J., Cowan, K. H., Curt, G. A., Clendeninn, N. J., & Chabner, B. A. (1983) · New England Journal of Medicine · doi:10.1056/nejm198311033091805 · Cited by 786
MACOP-B Chemotherapy for the Treatment of Diffuse Large-Cell Lymphoma
KLIMO, P., & CONNORS, J. M. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-102-5-596 · Cited by 664
Etoposide (VP-16–213): Current Status of an Active Anticancer Drug
O'Dwyer, P. J., Leyland-Jones, B., Alonso, M. T., Marsoni, S., & Wittes, R. E. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503143121106 · Cited by 358
Gordon, L. I., Harrington, D., Andersen, J., Colgan, J., Glick, J., Neiman, R., Mann, R., Resnick, G. D., Barcos, M., Gottlieb, A., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211053271903 · Cited by 325
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics
Rowinsky, E. K., & Donehower, R. C. (1991) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(91)90086-2 · Cited by 321
The effect of compliance with treatment on survival among patients with hematologic malignancies.
Richardson, J. L., Shelton, D. R., Krailo, M., & Levine, A. M. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.2.356 · Cited by 305
Sonneveld, P., de Ridder, M., van der Lelie, H., Nieuwenhuis, K., Schouten, H., Mulder, A., van Reijswoud, I., Hop, W., & Lowenberg, B. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2530 · Cited by 280
Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high- risk" disease?
Shipp, M. (1994) · Blood · doi:10.1182/blood.v83.5.1165.1165 · Cited by 278
SHIPP, M. A., HARRINGTON, D. P., KLATT, M. M., JOCHELSON, M. S., PINKUS, G. S., MARSHALL, J. L., ROSENTHAL, D. S., SKARIN, A. T., & CANELLOS, G. P. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-6-757 · Cited by 277
Self-citationVose, J. M., Armitage, J. O., Weisenburger, D. D., Bierman, P. J., Sorensen, S., Hutchins, M., Moravec, D. F., Howe, D., Dowling, M. D., & Mailliard, J. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1838 · Cited by 272
High-dose methotrexate: a critical reappraisal.
Ackland, S. P., & Schilsky, R. L. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.12.2017 · Cited by 254
Richardson, J. L., Marks, G., & Levine, A. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.11.1746 · Cited by 180
Metadata
- Authors
- Skarin, A. T., Canellos, G. P., Rosenthal, D. S., Case, D. C., MacIntyre, J. M., Pinkus, G. S., Moloney, W. C., & Frei, E.
- Venue
- Journal of Clinical Oncology
- Published
- 1983-02
- Volume
- 1
- Issue
- 2
- Pages
- 91-98
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1949042228
- Cited by
- 334
- References
- 5
- FWCI
- 28.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.